Navigation Links
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN

Interim analysis of Phase 2 comparative study showed significant results in favor of alemtuzumab versus Rebif

CAMBRIDGE, Mass. and WAYNE, N.J., May 02, 2007 /PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer HealthCare Pharmaceutical today announced detailed interim results from the CAMMS223 Phase 2 study. This interim analysis of all patient data through at least twenty-four months from the start of the study for all patients showed that a once-yearly cycle of alemtuzumab treatment had a statistically significant impact on reducing the frequency of relapses and the sustained accumulation of disability in early active relapsing remitting multiple sclerosis (RRMS) patients compared to Rebif(R) (interferon beta-1a).

The data were presented yesterday at the 59th Annual Meeting of the American Academy of Neurology (AAN) in Boston by Dr. Alasdair J. Coles, Ph.D., MRCP, Addenbrooke's Hospital, University of Cambridge, United Kingdom. This is the first time that an analysis of the primary and secondary endpoints has been presented in full.

Dr. Coles' presentation showed patients taking alemtuzumab at the high dose experienced an 87 percent reduction in the risk for relapse (p<0.0001) and a 66 percent reduction in the risk for progression of clinically significant disability (p<0.0098) when compared to patients treated with Rebif. At the low dose, patients taking alemtuzumab experienced similar results, with a 72 percent reduction in the risk for relapse (p<0.0001) and an 88 percent reduction in the risk for progression of clinically significant disability (p<0.0008) compared with patients treated with Rebif. Patients in both alemtuzumab arms also achieved a statistically significant reduction in disability compared with their pre-treatment baseline, as measured by their Extended Disability Status Scale (EDSS) scores.

"Although several therapies are already available to treat MS, patients stil
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:9/29/2014)... SAN DIEGO , 29 septembre ... désignée Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences ... d,un accord de fusion définitif en vertu duquel ... actions ordinaires en circulation d,Ambit Biosciences à 15 ... d,une offre publique d,achat qui sera suivie d,une ...
(Date:9/29/2014)...  Bob Pack, who lost his two young children ... Medical Association to immediately cease airing a television ad ... Mercury News called "shamelessly deceptive" and of which the ... believe about the measure is wrong." ... that doctors check California,s existing ...
(Date:9/29/2014)... Sept. 29, 2014  Volcano Corporation (Nasdaq: ... improving patient and economic outcomes on a global ... coronary and peripheral visualization, physiology diagnostics and therapies, ... Board of Directors from Engaged Capital, LLC.  The ... Volcano welcomes the perspectives of its ...
Breaking Medicine Technology:Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5Volcano Issues Statement Regarding Letter From Engaged Capital 2Volcano Issues Statement Regarding Letter From Engaged Capital 3
... studied the treatment of pregnant women with hepatitis B virus ... study concluded that both the mothers benefited from treatment and ... weeks postbirth. The study presenter and co-investigator Calvin ... as hepatitis B is difficult to eradicate and currently there ...
... POINT, Calif., Nov. 1, 2010 The Global ... organization that aims to raise awareness about the ... 7,000 Bracelets for Hope™ campaign. The 7,000 Bracelets ... to an estimated 7,000 different chronic, life-threatening and ...
Cached Medicine Technology:Telbivudine Given to Mothers With Hepatitis B Reduces Infection Rate in Infants 2Telbivudine Given to Mothers With Hepatitis B Reduces Infection Rate in Infants 37,000 Bracelets For Hope™ - A Rare Disease Awareness Campaign 27,000 Bracelets For Hope™ - A Rare Disease Awareness Campaign 3
(Date:9/30/2014)... Seattle, WA (PRWEB) September 30, 2014 ... Intelligence, proudly announced today that the Department of ... Office as its Enterprise End User Business ... to better support our nation’s veterans by enabling ... obtained through BI Office’s powerful enterprise analytics and ...
(Date:9/30/2014)... September 30, 2014 “Biology and ... Bryan W. Brickner, “and it’s about naming rights.” ... Science , new on the Bryan William Brickner ... the National Institutes of Health (PubMed). The post ... sleep disturbances, REM transitions, aging with THC, the ...
(Date:9/30/2014)... A trailblazer at heart, Dr. Scott Katzman stays ... breakthroughs in spine repairs. His newest appreciation has been ... in which he has implanted the Mobi-C Artificial Disc ... art and mimic normal human disc motion. Dr. Katzman goes ... to be an exceptional replacement device for failing fusions. Patients ...
(Date:9/30/2014)... 3M has added four new thin VHB products to ... 5906 , 3M 5907 , 3M 5908 , ... create the strongest bond possible to a wide range of ... difficult surfaces such as paints, low surface energy plastics, and ... are designed specifically for electronic device engineers and electronics manufacturers. ...
(Date:9/30/2014)... RI (PRWEB) September 30, 2014 Dogs are ... Oftentimes, this involves spending time in the car travelling from ... canines have free run of the vehicle; however, this is ... owner as well. Royal Flush Havanese shares with ... always be routine practice. , There are many ways a ...
Breaking Medicine News(10 mins):Health News:U.S. Department of Veterans Affairs Takes Its Analytic Capabilities to the Next Level with BI Office from Pyramid Analytics 2Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 2Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 3
... , The 10th Annual Conference and Exposition of ... Society for Human Resource Management --HR: Building Bridges to Success" in ... July 23-24 , , ... that employee wellness programs that help workers lose weight or quit smoking, for instance, ...
... MUMBAI, July 23 , ... Activity by the Clinical Investigator Dr. A Bhattacharya Working,at the GG ... - Glenmark Not Only Acts as the Whistle-Blower but Also ... After receiving approval from the Drug Controller General of India(DCGI),for ...
... 23 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ), ... and marketing biopharmaceutical,products, today announced that it will release ... after the US market closes on Tuesday,August 11, 2009. ... 3SBio,s senior management will host a,conference call at 5:00 ...
... ... classes. As a special promotion eMindful is offering unlimited classes for the month of ... yoga practice, or has wanted to explore the health benefits of yoga, to participate at ... ...
... ... dentist Dr. Robert L. Williamson one of America,s Top Dentists. , ... Raleigh, North Carolina (PRWEB) July 23, 2009 -- For ... award for being one of the top dentists in the United States. The Consumer,s Research ...
... ... top Orthopedic Surgeons in the greater Atlanta metro area for the second consecutive time. ... skilled, exceptional, and ,most-trusted, sports medicine specialist. , ... Atlanta, GA (PRWEB) July 23, 2009 -- Spero G. Karas M.D. ...
Cached Medicine News:Health News:Employee Wellness Programs Demonstrate Positive Return on Investment for Businesses 2Health News:Employee Wellness Programs Demonstrate Positive Return on Investment for Businesses 3Health News:Glenmark Brings to the Notice of the Authorities Irregularities of the Clinical Investigator at its Jamnagar Site in Gujarat 2Health News:3SBio Inc. to Report 2009 Second Quarter Earnings on August 11, 2009 2Health News:3SBio Inc. to Report 2009 Second Quarter Earnings on August 11, 2009 3Health News:eMindful.com Launches Live, Interactive Online Yoga Classes 2Health News:eMindful.com Launches Live, Interactive Online Yoga Classes 3Health News:Dr. Robert L. Williamson III Once Again Selected As One of America's Top Dentists 2Health News:Atlanta Sports Medicine Doctor Spero Karas Wins 'Atlanta's Top Doctors' Honor Again 2Health News:Atlanta Sports Medicine Doctor Spero Karas Wins 'Atlanta's Top Doctors' Honor Again 3
... Aplicare's Saturated Swabsticks are packaged ... Each 4 inch Swabstick is saturated ... solution. Each package is terminally sterilized, ... the patient. It acts as a ...
... Antiseptic Antibacterial that does not ... 30 seconds, destroys over 99% ... for cleansing of minor wounds, ... disinfection of personal utensils and ...
... professional degerming, pre-op and post-op procedures. ... quaternary and substituted phenolic active ingredients ... and surfactants. Unprecedented efficacy on all ... 30 seconds. Techni-Care represents a new ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
Medicine Products: